Herpes Zoster (Shingles) Global Clinical Trials Review 2024: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type And End-Point Status
( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Herpes Zoster (Shingles) - Global Clinical Trials Review, 2024" clinical trials has been added to ...
manilatimes11m
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference at 6:45 p.m. ET / 3:45 p.m. PT on January 14, 2025. The webcast will be accessible from Royalty Pharma's "Events” page ...
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the BoardInterim Changes to ...
ENDPOINTS NEWS43m
An­oth­er biotech scoops up as­set from Chi­na-based Keymed and nabs $180M
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors ...
devdiscourse45m
Neuberg Diagnostics Secures Landmark Investment from Kotak Alt
Neuberg Diagnostics, a diagnostics chain headquartered in India, raised Rs 940 crore from Kotak Alternate Asset Managers Ltd.
money.rediff45m
Neuberg Diagnostics Secures Rs 940 Cr Funding for Expansion
Neuberg Diagnostics, a Chennai-based diagnostics chain, has secured Rs 940 crore from Kotak Alt, becoming the largest ever ...
Kotak Fund invests ₹940 crore in IPO-bound Neuberg Diagnostics
Kotak Strategic Situations India Fund II invests ₹940 crore in Neuberg Diagnostics for expansion and IPO preparation.